Netflix Inc. faces a trademark suit that threatens its top-viewed film franchise as it expands into concerts and branded goods. The owner of Demon Hunter is seeking a federal court order to stop the use of “KPop Demon Hunters” on music, live events and merchandise. Damages have not been detailed.
Demon Hunter v. Netflix · Case 2:26-cv-09191
August 19, 2026 · 4:00 p.m. EDT close
| Firm | View | Target | Upside |
|---|---|---|---|
| Argus | Buy | $265 | 19.3% |
| Tigress | Buy | $305 | 37.3% |
| BNP Paribas | Outperform | $300 | 35.0% |
| JPMorgan | Overweight | $290 | 30.5% |
| RBC | Outperform | $265 | 19.3% |
| Stock | Consensus | Avg target |
|---|---|---|
| AVGO · 48 | Strong Buy | $527.88 |
| MRVL · 43 | Strong Buy | $256.91 |
| GOOGL · 64 | Strong Buy | $427.52 |
| Broker | Date | View | Target | Upside* |
|---|---|---|---|---|
| Barclays | Aug 18 | BUY | 450p | 18.5% |
| Deutsche Bank | Aug 13 | BUY | 435p | 14.5% |
| Goldman Sachs | Jul 28 | BUY | 490p | 29.0% |
| Jefferies | Jul 22 | BUY | 460p | 21.1% |
| J.P. Morgan | Jul 21 | BUY | 450p | 18.5% |
| Company | Ticker | Price | Day move | Timestamp, BST |
|---|---|---|---|---|
| Marks & Spencer | LON:MKS | 379.80p | −1.22% | 09:58:31 |
| NEXT | LON:NXT | 15,015p | −0.46% | 09:59:40 |
| JD Sports | LON:JD | 78.88p | −15.60% | 10:00:39 |
| Associated British Foods | LON:ABF | 2,031p | +0.30% | 09:59:15 |
Bronco and Bronco Sport already represent one in every 6.4 Ford-brand U.S. vehicles. A wider family can improve mix only if it adds buyers rather than shifting them from Ranger or other Ford SUVs.
Recall letters are due to start Aug. 24 for 565,691 Broncos and Bronco Raptors. The reported wiring defect can short-circuit and raise fire risk. Ford will install sheathing free.
Market data: August 19, 2026 close, 16:00 EDT
Prepared after the U.S. session
Highest close in about three years
Phase 3 melanoma readout
One session, Financial Times estimate
Close × 399.24M shares
Investor read: the market priced a platform, not just a melanoma product. The $44 billion value gain equals about 14.7× Barclays’ $3 billion estimate for 2035 melanoma sales.
INTerpath-001 enrolled 1,137 patients with resected stage IIB-IV melanoma. No new safety signal was reported.
| Firm | View | Target |
|---|---|---|
| Piper Sandler | Overweight | $77 |
| Goldman Sachs | Neutral | $67 |
| Citigroup | Neutral | $60 |
| RBC Capital | Sector Perform | $45 |
| Wolfe Research | Underperform | $25 |
The $174.38 close is 126% above the old high target and 243% above the $50.84 consensus. These targets have not absorbed the trial result.
Bars share a $44 billion scale. The sales figure is an analyst estimate for melanoma in 2035, not company guidance.
| Next U.S. session | August 20, 09:30 EDT |
| Analyst model resets | Watch targets and probability assumptions |
| Medical presentation | Date not yet disclosed |
| Regulatory path | Companies are already in discussions |
| Possible availability | 2027, subject to approval |
CBA's earnings remain solid. The share price still carries a large premium, and analysts see another 22% downside to their average target.
Trailing earnings multiple compared with Australia's other major banks.
Year ended June 30, 2026.
| Measure | Result | YoY |
|---|---|---|
| Cash profit | A$10.98bn | +7% |
| Pre-provision profit | A$16.47bn | +6% |
| Net interest margin | 2.05% | +3bp |
| Operating expense | A$13.76bn | +6% |
| Impairment expense | A$788m | +9% |
| Return on equity | 14.0% | +50bp |
STRONG SELL • 14 analysts • Aug. 13 update
Stable mortgage applications, contained arrears and a steady 2.05% margin would support CBA's quality argument.
Higher credit losses, weaker margins or FY27 investment above A$2.4 billion would make a peer-like multiple harder to avoid.
CET1 is 12.0%, above the 10.25% regulatory minimum. The full-year dividend rose 4% to A$5.05 a share.
The market is pricing a cleaner FY27 before brokers have caught up.
Behring supplies roughly 72% of group revenue. Vifor revenue is guided about 25% lower in FY27.
Sources: TradingView, CSL FY26 results summary, S&P Global analyst poll and CSL investor calendar. Financial figures are in US dollars unless marked A$. Market data as of 19 Aug 2026, 16:10 AEST.
The next share unlock is large enough to change trading. Revenue growth is fast enough to keep buyers interested. The tape decides which force wins.
Closing prices in U.S. dollars. The stock remains above the IPO price but has slipped 4.5% since Monday.
Eligible does not mean sold. It does show the size of the overhang.
Revenue and adjusted EBITDA accelerated. Capital spending still ran at 2.4 times revenue.
| Measure | Q2 2026 | Change |
|---|---|---|
| Revenue | $7.81B | +92% |
| Adjusted EBITDA | $3.50B | +191% |
| Net loss | $541M | Improved $467M |
| Capital spending | $18.4B | 2.4× revenue |
| AI revenue | $2.56B | +247.5% |
| Connectivity revenue | $4.29B | +65.8% |
Latest published calls through August 18. Upside is measured from $139.65.
| Firm | Call | Target | Gap |
|---|---|---|---|
| Morgan Stanley | Buy | $300 | +114.8% |
| Deutsche Bank | Buy | $235 | +68.3% |
| Clear Street | Buy | $217 | +55.4% |
| UBS | Buy | $210 | +50.4% |
| Phillip Securities | Sell | $75 | -46.3% |
| Measure | Result | Change |
|---|---|---|
| Reported pre-tax profit | $19.5bn | +23% |
| Adjusted pre-tax profit | $20.4bn | +6% CER |
| Reported revenue | $37.7bn | +11% |
| Banking NII | $22.9bn | +$1.6bn |
| Annualised RoTE | 18.2% | Above 17% target |
| Gauge | Latest | Reference |
|---|---|---|
| CET1 ratio | 14.1% | 14.0%-14.5% range |
| Distance from floor | 0.1 point | Thin |
| Second interim dividend | $0.10/share | Approved |
| Payout target | 50% | 2026-2028 |
| 2026 NII outlook | At least $46bn | Raised |
| Credit-cost outlook | ~45 bp | Above 30-40 bp normal |
| View | Target | Vs. close |
|---|---|---|
| 17-analyst average | 1,485.6p | −0.8% |
| Goldman Sachs · Buy | 1,860p | +24.2% |
| BofA · Buy | 1,720p | +14.9% |
| Morgan Stanley · Hold | 1,674p | +11.8% |
| UBS · Hold | 1,620p | +8.2% |
| JPMorgan · Hold | 1,450p | −3.2% |
Arm's premium amplifies sensitivity to growth misses and higher bond yields.
Total revenue
| View | Target | vs. close |
|---|---|---|
| Morgan Stanley · Equal Weight | $465 | -0.3% |
| D.A. Davidson · Buy | $550 | +17.9% |
| Consensus · Strong Buy | $608 | +30.4% |
| Rosenblatt · Buy | $700 | +50.1% |
The full published range spans $365 to $1,250 across 51 analysts.
Price data: August 19, 2026 close
Captured 23:20 CEST / 17:20 EDT
$937.11
-0.39% Wednesday
-7.4%
From Monday’s $1,011.75
$1.06tn
TradingView estimate
$1,507.79
+60.9% implied
The stock gave back Monday’s policy-led gain in one session.
Micron trades at 3.2× SK hynix’s trailing P/E.
| Firm | Rating | Target | Implied return |
|---|---|---|---|
| KeyBanc | Buy | $1,750 | +86.7% |
| UBS | Buy | $1,625 | +73.4% |
| Citi | Buy | $1,150 | +22.7% |
| ThinkEquity | Buy | $900 | -4.0% |
| Survey average | Strong Buy | $1,507.79 | +60.9% |
| Scenario | Share price | Implied value* | Change |
|---|---|---|---|
| Survey high | $2,200 | $2.49tn | +$1.43tn |
| Survey average | $1,507.79 | $1.71tn | +$646bn |
| Current | $937.11 | $1.06tn | — |
| Survey low | $361 | $408bn | -$652bn |
*Preliminary proportional estimates using current price and market capitalization.
Memory pricing: DRAM and NAND contract checks
Rates: U.S. two-, five- and seven-year auctions, Aug. 25–27
AI spend: customer capex and HBM allocation updates
Micron has no earnings report scheduled for the coming week.
TradingView for closing price, market value and peer multiples; Associated Press for Tuesday’s selloff; Barron’s for memory pricing and prior-week close; Investing.com for analyst consensus. Targets are not guarantees.
| View | Rating | Target | Signal |
|---|---|---|---|
| 45-analyst poll | Strong Buy | HK$692.92 | 55% above close |
| JPMorgan | Overweight | HK$690 | Maintained |
| Benchmark | Buy | HK$625 | Cut from HK$700 |
| Morgan Stanley | Overweight | HK$550 | Cut from HK$650 |
AI is already helping advertising, games and cloud. The valuation case now depends on turning that demand into cash before capex stays near peak levels for too long.
Watch next: HK$440 support, Alibaba’s AI-spending update, cloud demand, and Tencent’s net-cash path.
Backlog is not revenue. The comparison shows why one difficult headline did not become a demand panic.
Market data: August 19, 2026, 13:35:22 EDT · USD · U.S. market open
The stock has recovered 57% from its annual low, yet remains one-third below its high. The easy “oversold” argument is fading.
Backlog growth remains above 20%. AI annual contract value crossed $1 billion.
The Q3 growth step-down is the next test. Federal on-premise revenue pulled forward into Q2 helped the prior beat.
| Company | Day | P/E | Below high |
|---|---|---|---|
| ServiceNow | +6.91% | 79.97× | −34.4% |
| Salesforce | +4.69% | 23.75× | −23.7% |
| Workday | +4.14% | 56.09× | −20.5% |
U.S. markets are open as of August 19, 2026, 12:28:12 EDT. The quotes shown below have a delay.
Final closes at 4:00 p.m. EDT are recorded for August 12–18, 2026; the point for August 19 is reported late at 12:12:19 EDT.
214,776,632 shares; present valuation is based on the June 30 position remaining the same.
| Derived measure | Value |
|---|---|
| Implied profit vs. investment | +$15.060B / +301% |
| 10% shift in INTC | ≈ $2.006B change in stake |
| Stake change / NVDA market cap | ≈ 0.04% |
INTC traded at $93.40 as of August 19, 2026, 12:13:03 EDT.
Figures in USD billions; periods refer to NVIDIA's fiscal calendar.
S&P Global consensus reviewed on August 19, 2026, at 12:28 EDT.
| Readout | Snapshot |
|---|---|
| Consensus | Strong Buy |
| Analysts | 61 |
| Target range | $180–$500 |
| Measure | Q2 FY26 | Change |
|---|---|---|
| Revenue | $22.19bn | +48% |
| AI semiconductor revenue | $10.8bn | +143% |
| Free cash flow | $10.26bn | +60% |
| Adjusted EBITDA | $15.24bn | +52% |
| Firm | Rating | Target |
|---|---|---|
| JPMorgan | Overweight | $580 |
| KeyBanc | Overweight | $575 |
| Bernstein | Outperform | $550 |
| S&P Global poll | Strong Buy | $527.88 avg. |
Financing expands the addressable market. Competition decides Broadcom’s share. The best evidence remains shipment growth and cash conversion—not the headline debt number.
